Innovative therapeutics

Investors

BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition
Oral Presentation to Include 78 Week Data with 6e13 Dose Cohort and 32 Week Data with 4e13 Dose Cohort from its Ongoing Phase 1/2 valoctocogene roxaparvovec (formerly BMN 270) Clinical Program, a Gene Therapy for Hemophilia A
Dec 6, 2017

SAN RAFAEL, Calif., Dec. 6, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition being held December 9-12, 2017 in Atlanta, Georgia. The presentation will report interim results from a Phase 1/2 study of valoctocogene roxaparvovec, an AAV5-FVIII Gene transfer in severe hemophilia.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

Listing of Posters and Presentations Related to BioMarin Products and Programs at the 59th American Society of Hematology Annual Meeting & Exposition

Oral Presentation – Late Breaking Abstract Session

Title

Authors

Achievement of Normal Circulating Factor VIII Activity Following BMN 270 AAV5-FVIII Gene Transfer: Interim, Long-Term Efficacy and Safety Results from a Phase 1/2 Study in Patients with Severe Hemophilia A

 

Presentation: December 11 at 7:30 AM

K. John Pasi, Savita Rangarajan, Benjamin Kim, Will Lester, David Perry, Bella Madan, Fatemeh Tavakkoli, Ke Yang, Glenn F. Pierce and Wing Yen Wong

Poster Presentations

Title

Authors

Impact of Pre-Existing Immunogenicity to AAV on Vector Transduction By BMN 270, an AAV5-Based Gene Therapy Treatment for Hemophilia A

 

Presentation: December 10 at 6:00-8:00 PM

Poster/Presentation: #3332

Brian Long, Krystal Sandza, Jennifer Holcomb, Juli Pherarolis, Lucy Crockett, Lillian Falese, Greg Hayes, Jeremy Arens, Charles A. O'Neill, Nancy Pryer, Carlos Fonck, Stephen Zoog and Christian Vettermann

Interim Analysis of Immunogenicity to the Vector Capsid and Transgene-Expressed Human FVIII in a Phase-1/2 Clinical Study of BMN 270, an AAV5-Mediated Gene Therapy for Hemophilia A

 

Presentation: December 11 at 6:00-8:00 PM

Poster/Presentation: #4611

Brian Long, Benjamin Kim, Wing Yen Wong, Ke Yang, Christian Vettermann, Nancy Pryer, Romain Hardet, Klaudia Kuranda, Philippe Veron, Federico Mingozzi, Glenn F. Pierce and Becky Schweighardt

About Hemophilia A

Hemophilia A is a genetic disease caused by the deficiency of clotting factor VIII. It is the most common type of hemophilia and occurs much more frequently in males; incidence is estimated to be 1 in 4,000-5,000 male births. People born with hemophilia produce little or no clotting factors. The two main types of hemophilia are A and B. People with hemophilia A are missing or have low levels of clotting factor VIII.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com.

Contact:




Investors:         

Media:

Traci McCarty     

Debra Charlesworth

BioMarin Pharmaceutical Inc.    

BioMarin Pharmaceutical Inc.

(415) 455-7558                    

(415) 455-7451

                                                                       

SOURCE BioMarin Pharmaceutical Inc.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information